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Objectives: To assess the attitudes of practitioners with respect 
to net ultrafiltration prescription and practice among critically ill 
patients with acute kidney injury treated with renal replacement 
therapy.
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Design: Multinational internet-assisted survey.
Setting: Critical care practitioners involved with 14 societies in 
80 countries.
Subjects: Intensivists, nephrologists, advanced practice provid-
ers, ICU and dialysis nurses.
Intervention: A cross-sectional survey.
Measurement and Main Results: Of 2,567 practitioners who 
initiated the survey, 1,569 (61.1%) completed the survey. Most 
practitioners were intensivists (72.7%) with a median duration of 
13.2 years of practice (interquartile range, 7.2–22.0 yr). Two third 
of practitioners (71.0%; regional range, 55.0–95.5%) reported 
using continuous renal replacement therapy with a net ultrafiltra-
tion rate prescription of median 80.0 mL/hr (interquartile range, 
49.0–111.0 mL/hr) for hemodynamically unstable and a maximal 
rate of 299.0 mL/hr (interquartile range, 200.0–365.0 mL/hr) for 
hemodynamically stable patients, with regional variation. Only 
a third of practitioners (31.5%; range, 13.7–47.8%) assessed 
hourly net fluid balance during continuous renal replacement 
therapy. Hemodynamic instability was reported in 20% (range, 
20–38%) of patients and practitioners decreased the rate of fluid 
removal (70.3%); started or increased the dose of a vasopressor 
(51.5%); completely stopped fluid removal (35.8%); and admin-
istered a fluid bolus (31.6%), with significant regional variation. 
Compared with physicians, nurses were most likely to report pa-
tient intolerance to net ultrafiltration (73.4% vs 81.3%; p = 0.002), 
frequent interruptions (40.4% vs 54.5%; p < 0.001), and unavail-
ability of trained staff (11.9% vs 15.6%; p = 0.04), whereas physi-
cians reported unavailability of dialysis machines (14.3% vs 6.1%; 
p < 0.001) and costs associated with treatment as barriers 
(12.1% vs 3.0%; p < 0.001) with significant regional variation.
Conclusions: Our study provides new knowledge about the 
presence and extent of international practice variation in net ul-
trafiltration. We also identified barriers and specific targets for 
quality improvement initiatives. Our data reflect the need for ev-
idence-based practice guidelines for net ultrafiltration. (Crit Care 
Med 2019; XX:00–00)
Key Words: fluid overload; net ultrafiltration; prescription; renal 
replacement therapy; survey
Fluid overload (FO) is prevalent in more than two thirds of critically ill patients with acute kidney injury and is independently associated with mortality (1–4). When 
FO is resistant to treatment with diuretics, clinicians fre-
quently use net ultrafiltration (UFNET) during renal replace-
ment therapy (RRT). This practice is based on studies (3, 5) 
that suggest UFNET may reduce morbidity and mortality and 
is supported by clinical practice guidelines (6). Nevertheless, 
several aspects of UFNET including the optimal timing, rate, or 
how to manage complications are unclear.
Emerging evidence from observational studies in crit-
ically ill patients suggests that higher UFNET rates, compared 
with lower UFNET rates, are associated with lower mortality in 
some studies (7) and increased mortality in others (8). Data 
from outpatients with end-stage renal disease also suggest that 
higher UFNET rates are associated with increased mortality (9–
12). Thus, we conducted a multinational survey of critical care 
practitioners to ascertain attitudes in prescription and practice 
of UFNET with the ultimate goal to inform research and quality 
improvement initiatives.
Specifically, we assessed 1) how practitioners determined 
diuretic resistance and criteria used for initiation and prescrip-
tion of UFNET; 2) modality of RRT, typical UFNET prescription, 
assessment of prescribed-to-delivered dose of UFNET, and eval-
uation of net fluid balance; 3) hemodynamic instability and 
management; 4) perceived barriers; and 5) attitudes related to 
timing of initiation of UFNET, need for a protocol, and equi-
poise to enroll patients in a clinical trial of protocol-based 
UFNET versus usual care.
METHODS
Survey Development and Testing
We conducted a worldwide, self-administered, cross-sec-
tional, internet-assisted, open survey of adult intensivists and 
nephrologists including trainees, advanced practice provid-
ers (i.e., nurse practitioners), and ICU and dialysis nurses, 
involving 14 critical care and nephrology societies in 80 
countries. We used rigorous survey methodology to design, 
test, and administer the survey instrument (13, 14). First, 
we conducted an unstructured interview with intensivists 
(n = 3), nephrologists (n = 2), advanced practice providers 
(n = 2), ICU (n = 2), and dialysis nurses (n = 2) at the Univer-
sity of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, to 
understand their attitudes toward fluid removal and drafted 
the instrument (phase I testing). Second, we piloted the in-
strument on critical care medicine (n = 2) and nephrology 
(n = 2) trainees, intensivists (n = 2), nephrologists (n = 2), 
advanced practice providers (n = 2), ICU (n = 2), and dialysis 
nurses (n = 2) at UPMC and Guy’s & St Thomas’ Hospital, 
London, United Kingdom, making revisions for readability 
and clarity (phase II testing).
The instrument was then pretested by the survey steer-
ing committee, who provided feedback on “Face-, Content-, 
and Criterion validity.” We assessed “test-retest reliability” by 
administering the instrument to four practitioners on two 
occasions separated by 2 weeks, and the final instrument con-
sisted of 25 questions examining five domains (eMethods 1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
F64). We used branched logic within the instrument to ask 
questions that are only appropriate for nurses (eMethods 2, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
F64). The final instrument (eMethods 3, Supplemental Digital 
Content 1, http://links.lww.com/CCM/F64) was approved by 
the University of Pittsburgh’s Human Research Protection 
Office and was endorsed by the European Society of Intensive 
Care Medicine (ESICM), Chinese Society of Critical Care 
Medicine (CSCCM), Japanese Society of Critical Care Medicine 
(JSCCM), the Society of Critical Care Medicine (SCCM), the 
Comprehensive Local Research Network (CLRN), and the 
National Institute of Health Research in the United Kingdom.
Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Online Clinical Investigation
Critical Care Medicine www.ccmjournal.org 3
Survey Administration
The survey prefaced by an invitation letter was administered 
using an online software (Qualtrics, Provo, UT). The survey 
was disseminated between January 6, 2018, and January 10, 
2019, via email to the members of the Australasian and New 
Zealand Intensive Care Society, British Association of Crit-
ical Care Nurses (BACCN), Canadian Critical Care Society, 
CSCCM, ESICM, Indian Society of Critical Care Medicine, 
Italian Society of Intensive Care, JSCCM, National Kidney 
Foundation, SCCM, Thailand Society of Critical Care Medi-
cine, and the CLRN (eMethods 2, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/F64). To expand the survey 
distribution and improve the response rates, individual societ-
ies sent reminders according to their policies and procedures.
The survey was also displayed on the website of the ESICM, 
American Association of Critical Care Nurses, CSCCM, Italian 
Society of Nephrology, as well as in the newsletter of BACCN. 
In China and Japan, the survey instrument was translated in 
Chinese and Japanese by two investigators (Z.P., K.K.). The 
survey was administered anonymously, and the IP addresses of 
individuals and information related to identity were not col-
lected. The survey was voluntary, and consent was implied if 
the participants responded, and no incentives were offered for 
survey completion. We adhered to the Checklist for Reporting 
Results of Internet E-surveys to report the data (15).
Statistical Analysis
Only complete questionnaires were included in the final analy-
ses. We present descriptive statistics as either proportions or 
median (interquartile range [IQR]), as appropriate and re-
gional data as range. In assessing proportions, we excluded 
“I do not prescribe/make decision,” “Other,” “I don’t know,” 
and “Not applicable” items. We assessed practice variation 
using the chi-square test and Wilcoxon rank sum or K-sample 
equality of medians test for binary and continuous outcomes, 
respectively. To compare regional differences for seven-point 
Likert-type responses, we collapsed ordinal categories into 
three groups (agree, neither agree nor disagree, and disagree). 
We did not impute any missing data and considered p values 
less than 0.05 to be statistically significant. All analyses were 
performed using STATA 15.0 (STATA Corp, College Station, 
TX) software. Thematic analysis was performed for the free-
text comments and lexical analysis for comments in English 
(eMethods 4, Supplemental Digital Content 1, http://links.
lww.com/CCM/F64) (16).
RESULTS
Practitioner Characteristics
The survey was disseminated to 56,840 members belonging 
to nine societies (eMethods 2, Supplemental Digital Content 
1, http://links.lww.com/CCM/F64). However, many practi-
tioners were members of multiple societies and received the 
survey more than once. Of 2,567 practitioners who initiated 
the survey, 1,569 practitioners (61.1%) completed and 998 
practitioners (38.9%) did not complete the questionnaire 
(eTable 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/F64) including 62 (2.4%) who opted out of the 
survey. Practitioners were from North America (34.1%), Eu-
rope (30.9%), Asia (28.9%), Oceania (2.9%), South America 
(2.7%), and Africa (0.5%; Table 1; and eTable 2, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F64). The most 
represented countries were the United States (29.6%), United 
Kingdom (11.5%), Japan (10.3%), China (10.1%), Italy (5.0%), 
India (3.2%), Canada (2.9%), and Australia (2.5%; Fig. 1; and 
eTable 3, Supplemental Digital Content 1, http://links.lww.
com/CCM/F64). Majority of practitioners were intensivists 
(72.7%) and ICU nurses (22.0%), and the median duration of 
clinical practice was 13.2 years (IQR, 7.2–22.0 yr). More than 
half (57.5%) practiced in a university-based hospital. eTable 4 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
F64) shows the distribution of responses by physicians and 
nurses.
Diuretic Resistance and Criteria Used for Initiation 
and Prescription of UFNET
Of intensivists, nephrologists, and advanced practice provid-
ers (77.1%), 44.2% (regional range, 33.3–55.0%) affirmed that 
they used a maximum 100–250 mg of furosemide equivalent 
per day before determining diuretic resistance with regional 
variation. Although more than half of practitioners in North 
America (55%) used 100–250 mg/d of furosemide, only a third 
in Europe (33.5%) and Oceania (33.3%) used this dose. For in-
itiation of UFNET, practitioners considered persistent oliguria/
anuria (42.4%; range, 22.2–51.1%) and pulmonary edema 
(16.0%; range, 13.3–37.5%). Although prescribing UFNET, half 
(52.2%; range, 44.8–75.0%) considered patient hemodynamic 
status and 19.0% (range, 10.5–22.3%) cumulative fluid bal-
ance with regional variation.
RRT Modality, UFNET Prescription, Assessment of 
Prescribed-to-Delivered UFNET Dose, and Evaluation 
of Net Fluid Balance
Intermittent Hemodialysis. Across regions, practitioners re-
ported that they treated a median of 10% (range, 1.0–45.5%) 
of patients with intermittent hemodialysis (IHD) (Table 2; 
and eTable 4, Supplemental Digital Content 1, http://links.
lww.com/CCM/F64) and 6.0% (range, 0.5–60%) with “slow” 
forms of IHD such as sustained low-efficiency dialysis, pro-
longed intermittent RRT, or extended daily dialysis. The typ-
ical median UFNET rate prescription was 2.0 L (IQR, 2.0–3.0; 
regional range, 2.0–2.5) per session. Only two third (70.0%; 
range, 50.0–97.5%) reported assessing prescribed-to-delivered 
dose of UFNET with significant regional variation.
Continuous RRT. Although two third (71.0%; range, 20.0–
95.5%) of practitioners indicated that they used continuous 
RRT (CRRT) as the first modality for UFNET, there was regional 
variation (Table 2). Respondents from Europe and Oceania re-
ported using CRRT in more than 90.0% of patients, whereas 
only 20.0% of patients in South America. For a hemodynam-
ically stable patient, typical initial UFNET prescription, as re-
ported by practitioners, was 125.0 mL/hr (IQR, 100.0–200.0; 
Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Murugan et al
4 www.ccmjournal.org XXX 2019 • Volume XX • Number XXX
TABLE 1. Practitioner Characteristics, Diuretic Dose, and Criteria Used for Initiation and 
Prescription of Net Ultrafiltration
Characteristic
Africa
(n = 8)
Asia
(n = 453)
Europe
(n = 485)
North  
America
(n = 535)
Oceania
(n = 45)
South  
America
(n = 43)
All
(n = 1,569)
Practitioner type, n (%)        
 Intensivist 8 (100) 397 (87.6) 365 (75.3) 246 (46) 34 (75.6) 36 (83.7) 1,086 (69.2)
 Nephrologist 0 14 (3.1) 4 (0.8) 11 (2.1) 1 (2.2) 2 (4.6) 32 (2.0)
 Intensivist and  
nephrologist
0 22 (4.9) 19 (3.9) 9 (1.7) 0 5 (11.6) 55 (3.5)
 Advanced practice  
provider
0 5 (1.1) 7 (1.4) 28 (5.2) 1 (2.2) 0 41 (2.6)
 ICU nurse 0 10 (2.2) 89 (18.3) 239 (44.7) 8 (17.8) 0 346 (22.0)
 Dialysis nurse 0 5 (1.1) 1 (0.2) 2 (0.4) 1 (2.2) 0 9 (0.6)
Years of practice,  
median (IQR)
16.8  
(14.0–21.0)
13.9  
(9.0–21.2)
16.3  
(10.0–23.9)
9.0  
(4.4–20.0)
20.0  
(15.0–27.0)
15.0  
(10.0–19.5)
13.2  
(7.2–22.0)
Hospital type, n (%)        
 University based 4 (50.0) 210 (46.4) 306 (63.1) 343 (64.1) 22 (48.9) 18 (41.9) 903 (57.5)
 Community based 1 (12.5) 112 (24.7) 110 (22.7) 149 (27.8) 2 (4.4) 11 (25.6) 385 (24.5)
 Government 3 (37.5) 96 (21.2) 42 (8.6) 28 (5.2) 18 (40.0) 7 (16.3) 194 (12.4)
 Other 0 35 (7.7) 27 (5.6) 15 (2.8) 3 (6.7) 7 (16.3) 87 (5.5)
Maximum dose of loop  
diuretic prescribed  
(furosemide equivalent),  
mg/d,a,b,c n (%)
       
 < 100 0 115 (26.3) 41 (10.4) 19 (6.5) 4 (11.1) 6 (14.0) 185 (15.3)
 100–250 3 (37.5) 209 (47.7) 132 (33.5) 160 (55.0) 12 (33.3) 19 (44.2) 535 (44.2)
 251–500 3 (37.5) 60 (13.7) 69 (17.5) 68 (23.4) 9 (25.0) 8 (18.6) 217 (18.0)
 501–750 0 14 (3.2) 25 (6.3) 9 (3.1) 1 (2.8) 2 (4.6) 51 (4.2)
 751–1,000 1 (12.5) 14 (3.2) 66 (16.7) 14 (4.8) 3 (8.3) 5 (11.6) 103 (8.5)
 > 1,000 1 (12.5) 11 (2.5) 30 (7.6) 5 (1.7) 1 (2.8) 1 (2.3) 49 (4.0)
Criteria used for UFNET  
initiation,a,c,d n (%)
       
 Persistent oliguria/ 
anuria (urine output  
< 0.5 mL/kg/hr for ≥ 
12 hr)
2 (25.0) 224 (51.1) 180 (45.6) 80 (27.2) 8 (22.2) 21 (48.8) 515 (42.4)
 Severe hypoxemia (Pao2/ 
Fio2 ratio < 150)
0 38 (8.7) 38 (9.6) 74 (25.2) 1 (2.8) 1 (2.3) 152 (12.5)
 Pulmonary edema with  
or without hypoxemia
3 (37.5) 72 (16.4) 66 (16.7) 39 (13.3) 7 (19.4) 7 (16.3) 194 (16.0)
 Cumulative fluid balance  
(> 1,000 mL)
0 11 (2.5) 19 (4.8) 16 (5.4) 5 (13.9) 3 (7.0) 54 (4.4)
 Fluid overload > 10%  
of body weight
0 15 (3.4) 21 (5.3) 19 (6.5) 2 (5.6) 3 (7.0) 60 (5.0)
 Ongoing need for fluids  
in the presence of 
oliguria
2 (25.0) 50 (11.4) 26 (6.6) 23 (7.8) 3 (8.3) 2 (4.6) 106 (8.7)
(Continued )
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Criteria used for UFNET  
prescription,a,d,e n (%)
       
 24-hr fluid balance 1 (12.5) 45 (10.3) 63 (15.9) 36 (12.2) 6 (16.7) 5 (11.6) 156 (12.8)
 Cumulative fluid balance 0 94 (21.5) 88 (22.3) 31 (10.5) 8 (22.2) 9 (20.9) 230 (18.9)
 Weight gain 0 28 (6.4) 31 (7.8) 9 (3.1) 0 1 (2.3) 69 (5.7)
 Radiographic features  
of fluid overload
0 16 (3.6) 7 (1.8) 6 (2.0) 0 2 (4.6) 31 (2.5)
 Hemodynamic status 
(heart rate, blood 
pressure, central 
venous pressure, pulse 
pressure variation, dose 
of vasopressors)
6 (75) 231 (52.7) 177 (44.8) 179 (60.8) 18 (50.0) 23 (53.5) 634 (52.2)
 Volume of anticipated 
fluid use in the next 
24 hr
0 8 (1.8) 10 (2.5) 3 (1.0) 1 (2.8) 1 (2.3) 23 (1.9)
 Arterial lactate 0 6 (1.4) 1 (0.2) 0 0 1 (2.3) 8 (0.7)
IQR = interquartile range, UTNET  = net ultrafiltration.
a Practitioners included intensivists, nephrologists, intensivists and nephrologists, and advanced practice providers. ICU and dialysis nurses were excluded from 
these questions.
b Practitioners include 1,210 (77.1%) from Africa (n = 8), Asia (n = 438), Europe (n = 394), North America (n = 291), Oceania (n = 36), and South America  
(n = 43).
c p < 0.001.
d Practitioners include 1,214 (77.3%) from Africa (n = 8), Asia (n = 438), Europe (n = 395), North America (n = 294), Oceania (n = 36), and South America  
(n = 43).
e p = 0.002.
TABLE 1. (Continued). Practitioner Characteristics, Diuretic Dose, and Criteria Used for 
Initiation and Prescription of Net Ultrafiltration
Characteristic
Africa
(n = 8)
Asia
(n = 453)
Europe
(n = 485)
North  
America
(n = 535)
Oceania
(n = 45)
South  
America
(n = 43)
All
(n = 1,569)
Figure 1. Geospatial distribution of survey responses. Blue shade represents the country of practice. Red circles represent the practitioners, and the 
size of the circle represents the number of practitioners per country who completed the survey. Total number of practitioners who completed the survey 
was 1,569.
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TABLE 2. Modality of Renal Replacement Therapy, Typical Net Ultrafiltration Prescription, 
and Evaluation of Net Fluid Balance
Practice  
Characteristics
Africa
(n = 8)
Asia
(n = 453)
Europe
(n = 485)
North  
America
(n = 
535)
Oceania
(n = 45)
South  
America
(n = 43)
All
(n = 1,569)
IHD, median (IQR)        
 Percent use in the last montha 45.5  
(40.0–51.0)
20.0  
(9.0–43.0)
5.0  
(0–25.0)
10  
(2.0–30.0)
1.0  
(0–10.0)
29.5  
(11.0–80.0)
10.0  
(2.0–30.0)
 Typical UFNET prescription, 
liters per sessionb
2.5  
(2.3–3.1)
2.2  
(2.0–3.0)
2.0  
(1.5–3.0)
2.0  
(2.0–3.0)
2.2  
(2.0–3.0)
2.5  
(2.0–3.0)
2.0  
(2.0–3.0)
Slow forms of IHD,c median (IQR)        
 Percent use in the last montha 60.0  
(5.0–81.0)
30.0  
(6.0–64.0)
1.0  
(0–20.0)
1.0  
(0–20.0)
0.5  
(0-20.0)
20.0  
(5.0–51.0)
6.0  
(0–34.0)
 Typical UFNET prescription, 
liters per sessiond
4.0  
(1.5–6.0)
2.0  
(1.2–3.0)
2.0 (1.0–2.9) 2.0  
(1.2–3.0)
2.0  
(1.5–3.0)
2.5  
(1.1–3.0)
2.0  
(1.1–3.0)
Percent of assessment  
of prescription- 
to-delivered UFNETa
97.5  
(88.0– 
100.0)
50.0  
(27.0– 
80.0)
79.5  
(21.0– 
100.0)
90.0  
(21.0– 
100.0)
90.0  
(12.0– 
100.0)
70.0  
(35.0– 
100.0)
70.0  
(25.0– 
100.0)
CRRT, median (IQR)        
 Percent use in the last montha 55.0  
(30.0– 
80.0)
66.5  
(29.0– 
90.0)
90.0  
(30.0– 
100.0)
60.0  
(20.0– 
90.0)
95.5  
(70.5– 
100.0)
20.0  
(0–50.0)
71.0  
(25.0– 
96.0)
 Initial UFNET rate for 
hemodynamically stable 
patient, mL/hra
300.0  
(204.0– 
301.0)
152.0  
(100.0– 
230.0)
149.0  
(100.0– 
200.0)
100.0  
(80.0 – 
200.0)
151.0  
(100.0– 
201.0)
152.0  
(105.0 – 
306.0)
125.0  
(100.0– 
200.0)
 Maximal UFNET rate for 
hemodynamically stable 
patient, mL/hre
501.0  
(500.0– 
502.0)
300.0  
(200.0– 
407.0)
300.0  
(201.0– 
352.0)
252.0  
(200.0– 
324.0)
300.5  
(251.0 – 
400.0)
300.0  
(201.0– 
403.0)
299.0  
(200.0– 
365.0)
 UFNET rate for hemodynamically 
unstable patient, mL/hra
200.0  
(106.0– 
297.0)
99.0  
(49.0– 
161.0)
98.0  
(51.0– 
108.0)
51.0  
(25.0– 
100.0)
92.5  
(51.0– 
148.0)
100.0  
(51.0– 
215.0)
80.0  
(49.0– 
111.0)
Method used to achieve UFNET  
using CRRT, n (%)a
       
By varying ultrafiltration rate only 1 (25.0) 171 (42.9) 191 (41.2) 223 (47.5) 18 (42.9) 9 (40.9) 613 (43.8)
 By varying replacement fluid 
rate only
0 22 (5.5) 32 (6.9) 17 (3.6) 9 (21.4) 0 80 (5.7)
 By varying both ultrafiltration  
and replacement fluid rate
2 (50.0) 191 (47.9) 191 (41.2) 143 (30.5) 13 (30.9) 13 (59.1) 553 (39.5)
How frequently did you check net 
fluid balance during CRRT? (hr), 
n (%)a
       
 1 1 (25.0) 76 (19.0) 121 (26.1) 224 (47.8) 16 (38.1) 3 (13.7) 441 (31.5)
 2 0 85 (21.3) 20 (4.3) 22 (4.7) 2 (4.8) 1 (4.5) 130 (9.3)
 4 1 (25.0) 88 (22.1) 40 (8.6) 42 (9.0) 3 (7.1) 4 (18.2) 178 (12.7)
 6 0 40 (10.0) 57 (12.3) 20 (4.3) 4 (9.5) 6 (27.3) 127 (9.1)
 8 0 45 (11.3) 63 (13.6) 25 (5.3) 1 (2.4) 1 (4.5) 135 (9.6)
 12 0 22 (5.5) 67 (14.5) 43 (9.2) 6 (14.3) 2 (9.1) 140 (10.0)
 24 0 27 (6.8) 55 (11.8) 45 (9.6) 6 (14.3) 3 (13.6) 136 (9.7)
CRRT, continuous renal replacement therapy, IHD, intermittent hemodialysis, IQR = interquartile range, UFNET  = net ultrafiltration.
a p < 0.001.
b p = 0.07.
c Slow forms of IHD include sustained low-efficiency dialysis, prolonged intermittent renal replacement therapy, or extended daily dialysis.
d p = 0.06.
e p = 0.19.
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range, 100.0–300.0). However, this varied across regions and 
also by practitioner type with physicians reporting higher rates 
than nurses (median rate, 149.0 vs 100.0 mL/hr; p < 0.001; 
and eTable 4, Supplemental Digital Content 1, http://links.
lww.com/CCM/F64). The maximal UFNET rate prescribed was 
299.0 mL/hr (IQR, 200.0–365.0; range, 300.0–501.0).
For hemodynamically unstable patients, the reported me-
dian UFNET rate was 80.0 mL/hr (IQR, 49.0–111.0; range, 
51.0–200.0) with regional variation. Among the top eight re-
spondent countries, the median UFNET prescription was lowest in 
Japan (40.0 mL/hr; IQR, 0–52.0), Canada, and the United States 
(51.0 mL/hr; IQR, 25.0–100.0) and highest in China (169.0 mL/
hr; IQR, 102.0–243.0; Fig. 2A; and eTable 5, Supplemental 
Digital Content 1, http://links.lww.com/CCM/F64). Across re-
gions, physicians reported higher median rates than nurses (92.0 
vs 52.0 mL/hr; p < 0.001). Practitioners achieved UFNET by vary-
ing the ultrafiltration rate alone in 43.8% (range, 25.0–47.5%) 
and by varying both the ultrafiltration and replacement fluid 
rates in 39.5% (range, 30.5–59.1%) with regional variation.
Only one third (31.5%; range, 13.7–47.8%) of practitioners 
reported evaluating the net fluid balance every 1 hour. Hourly 
net fluid balance was evaluated only by 48.0% of practitioners 
in North America and 19.0% in Asia. Among the top eight re-
spondent countries, only 51.0% of practitioners in the United 
States and the United Kingdom, 40.5% in Australia, and 5.3% 
in Italy evaluated hourly fluid balance. Physicians evaluated 
less frequently than nurses (19.2% vs 66.9%; p < 0.001) (eTable 
4 and eFig. 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/F64).
Hemodynamic Instability and Its Management
Practitioners reported new hemodynamic instability as char-
acterized by onset or worsening of tachycardia, hypotension, 
or a need to start or increase the dose of vasopressors in 20.0% 
of patients (range, 20.0–38.0%; Table 3). When hemodynamic 
instability occurred, two third of practitioners (70.3%; range, 
60.4–75.0%) reported that they decreased the rate of fluid 
removal; half (51.5%; range, 37.5–57.2%) started a new or 
increased the dose of a vasopressor; one third (35.8%; range, 
25.0–43.5%) completely stopped fluid removal, and a third 
(31.6%; range, 25.0–36.5%) administered a fluid bolus with 
significant regional variation.
Compared with physicians, nurses were more likely to 
report the following interventions: decrease fluid removal 
Figure 2. Net ultrafiltration rates and attitudes by practitioner type. A, Boxplot summaries of initial and maximal net ultrafiltration rates for 
hemodynamically stable patients and typical net ultrafiltration rates for hemodynamically unstable patients for the top eight respondent countries. The 
vertical box represents the 25th percentile (bottom line), median (middle line), and 75th percentile (top line) values. The lowest datum (lower whisker) 
represents 1.5 times the interquartile range of the lower quartile, and the highest datum (upper whisker) represents 1.5 times the interquartile range of 
the upper quartile. Circles represent outliers. Net ultrafiltration rates varied significantly across countries (p < 0.001 for all three groups). B, Interventions 
performed for hemodynamic instability during net ultrafiltration. Compared with physicians, nurses were more likely to cite interventions such as decrease 
or stop fluid removal, administer a fluid bolus, start or increase the dose of vasopressors, or administer albumin or mannitol bolus (p < 0.05 for all 
responses). C, Perceptions related to barriers for successful implementation of net ultrafiltration. Compared with physicians, nurses were more likely to 
cite barriers such as patient intolerance, frequent interruptions, and unavailability of trained staff (p < 0.05 for all responses), whereas physicians were 
more likely to cite unavailability of dialysis machines and cost (p < 0.001).
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rate (68.7% vs 75.0%; p = 0.01); stop fluid removal (42.9% 
vs 33.4%; p = 0.001); administer fluid bolus (36.1% vs 
30.1%; p = 0.02); start or increase vasopressor dose (63.1% 
vs 47.5%; p < 0.001); and administer albumin or mannitol 
bolus (30.6% vs 16.9%; p < 0.001) (Fig. 2B; and eTable 
6, Supplemental Digital Content 1, http://links.lww.com/
CCM/F64).
Perceived Barriers to UFNET
Patient intolerance, as reported by practitioners, was the 
most common barrier (75.4%; range, 72.1–79.4%) followed 
by frequent interruptions (44.0%; range, 18.6–71.1%) and 
under prescription of UFNET (15.3%; range, 4.6–37.5%). 
Compared with physicians, nurses were most likely to re-
port patient intolerance (73.4% vs 81.3%; p = 0.002), 
TABLE 3. Hemodynamic Instability, Interventions Performed, and Perceived Barriers to Net 
Ultrafiltration
Practice Characteristics
Africa
(n = 8)
Asia
(n = 453)
Europe
(n = 485)
North  
America
(n = 535)
Oceania
(n = 45)
South  
America
(n = 43)
All
(n = 1,569)
Percentage of patients developing 
new hemodynamic instability 
during UFNET,a median (IQR)
38.0  
(20.0–50.0)
25.0  
(10.0–40.0)
20.0  
(10.0–30.0)
25.0  
(10.0–41.0)
20.0  
(10.0–25.0)
30.0  
(17.5–50.0)
20.0  
(10.0–35.0)
Interventions performed for hemo-
dynamic instability,b n (%)
       
 Decrease the rate of fluid 
removala
6 (75.0) 320 (70.6) 340 (70.1) 379 (70.8) 32 (71.1) 26 (60.4) 1,103 (70.3)
 Completely stop fluid removala 2 (25.0) 139 (30.6) 164 (33.8) 233 (43.5) 13 (28.8) 11 (25.6) 562 (35.8)
 Make no changes to fluid removal 
ratec
0 11 (2.4) 18 (3.7) 19 (3.5) 5 (11.1) 0 52 (3.3)
 Administer a fluid bolusd 2 (25.0) 131 (28.9) 177 (36.5) 158 (29.5) 14 (31.1) 14 (32.5) 496 (31.6)
 Start or increase the dose of a 
vasopressore
3 (37.5) 204 (45.0) 249 (51.3) 306 (57.2) 24 (53.3) 22 (51.2) 808 (51.5)
 Switch to alternative modalityf 0 27 (5.9) 16 (3.3) 31 (5.8) 3 (6.6) 6 (13.9) 83 (5.3)
 Administer albumin or mannitol 
bolusa
0 62 (13.6) 65 (13.4) 174 (32.5) 12 (26.7) 6 (13.9) 319 (20.3)
Perceived barriers to UFNET,b n (%)        
 Patient intolerance (e.g., 
hypotension)a
6 (75.0) 336 (74.1) 352 (72.6) 425 (79.4) 34 (75.5) 31 (72.1) 1,184 (75.4)
 Under prescriptiong 3 (37.5) 55 (12.1) 74 (15.2) 94 (17.5) 13 (28.9) 2 (4.6) 241 (15.3)
 Frequent interruptions (e.g., trip to 
CT scan, operating room, filter 
clotting, catheter malfunction)a
3 (37.5) 164 (36.2) 220 (45.3) 263 (49.1) 32 (71.1) 8 (18.6) 690 (44)
 Inability to titrate fluid removalh 0 41 (9.0) 22 (4.5) 52 (9.7) 4 (8.9) 5 (11.6) 124 (7.9)
 Unavailability of adequately 
trained nursing staffi
3 (37.5) 67 (14.7) 36 (7.4) 89 (16.6) 1 (2.2) 6 (14.0) 202 (12.8)
 Unavailability of dialysis 
machinesj
2 (25.0) 101 (22.2) 30 (6.2) 50 (9.1) 0 9 (21.0) 192 (12.2)
 Cost associated with treatmenta 2 (25.0) 110 (24.2) 23 (4.7) 16 (3.0) 0 3 (6.9) 154 (9.8)
IQR = interquartile range, UFNET  = net ultrafiltration.
a p < 0.001.
b Multiple responses possible.
c p = 0.30.
d p = 0.04.
e p = 0.002.
f p = 0.04.
g p = 0.21.
h p = 0.83.
i p = 0.04.
j p = 0.01.
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interruptions (40.4% vs 54.5%; p < 0.001), and unavail-
ability of staff (11.9% vs 15.6%; p = 0.04), whereas physi-
cians reported unavailability of dialysis machines (14.3% 
vs 6.1%; p < 0.001) and cost as barriers (12.1% vs 3.0%; 
p < 0.001) (Fig. 2C; and eTable 6, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/F64).
Across regions, there was variation in perceived barriers 
(Table 3). For instance, unavailability of trained nursing staff 
was a barrier in China (25.3%), India (15.7%), and the United 
States (16.6%), and unavailability of dialysis machines in china 
(29.7), Japan (20.0%), United Kingdom (17.2%), and India 
(17.6%). Whereas, cost was a barrier in China (46.8%) and 
India (27.4%).
Attitudes Related to Timing, Use of Protocol, and 
Enrolling Patients in a Clinical Trial of Protocol-Based 
UFNET
Across regions, most practitioners (90.0%; range, 84.5–
91.7%) agreed that early UFNET would be beneficial (eTables 
7 and 8 and eFig. 2, Supplemental Digital Content 1, http://
links.lww.com/CCM/F64), and a protocol (81.4%; range, 
62.3–88.3%) outlining the rate, volume, and duration of 
UFNET would be useful, with significant regional variation. Al-
though two thirds (78.3%; range, 72.7–83.7%) indicated that 
they would be agreeable to enroll patients in a clinical trial 
comparing protocol-based UFNET versus usual care with phy-
sicians more willing to enroll than nurses (82.3% vs 66.1%; 
p < 0.001) (eFig. 2B, Supplemental Digital Content 1, http://
links.lww.com/CCM/F64).
Thematic Analysis of Comments
Of 1,173 physicians and 396 nurses, 355 (30.3%) and 103 
(26.0%) provided comments. Thematic analysis revealed five 
common themes (eTable 9, Supplemental Digital Content 1, 
http://links.lww.com/CCM/F64) including tools to facilitate 
UFNET, organizational-, clinician-, patient-, and RRT-related 
factors. Of these, prescription-related factors (9.8%) and the 
use of functional hemodynamic monitoring (8.7%) were pre-
dominant themes. Several comments also revealed suggestions 
for research and quality improvement initiatives (eTable 10, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
F64). Lexical analysis revealed top five nonconjunctive terms: 
“fluid” (168 words), “patient” (132), “removal” (93), “CRRT” 
(78), and “treatment” (42) (eFig. 3, Supplemental Digital Con-
tent 1, http://links.lww.com/CCM/F64).
DISCUSSION
In this multinational survey, we found significant regional 
variation in diuretic dosing, criteria used for initiation and 
prescription of UFNET, modality of RRT, assessment of pre-
scribed-to-delivered dose during IHD, rate of UFNET during 
CRRT, evaluation of net fluid balance and method used to 
achieve UFNET, frequency and management of hemodynamic 
instability, perceived barriers, benefit of using a protocol, and 
willingness to enroll in a clinical trial of protocol-based UFNET 
versus usual care.
There was also variation in practice as reported by physi-
cians and nurses. Physicians reported higher UFNET rates, 
whereas nurses reported higher interventions for managing 
hemodynamic instability. Nurses reported patient intoler-
ance, frequent interruptions, and unavailability of staff as 
barriers, whereas physicians reported unavailability of dial-
ysis machines and cost. Physicians were more willing to enroll 
patients in clinical trials. Thematic analysis revealed predomi-
nantly prescription-related issues and the need for functional 
hemodynamic monitoring to guide UFNET.
Our survey findings have several implications. First, under-
standing and addressing practice variation in UFNET are im-
portant because it might be associated with poor outcomes. 
Practice variation in other ICU care processes such as mechan-
ical ventilation and sedation use has been associated with poor 
outcomes, and interventions to reduce practice variation have 
resulted in improved outcomes (17, 18). Second, we found 
suboptimal practice patterns such as infrequent assessment of 
net fluid balance during CRRT; use of high UFNET rates, which 
has been associated with poor outcomes; and barriers such as 
frequent interruptions, lack of trained staff, unavailability of 
dialysis machines, and cost. By increasing clinician awareness 
about these issues, our survey is likely to result in quality im-
provement initiatives. Third, by providing normative data on 
practice patterns, our survey will inform future trial design and 
aid development of evidence-based guidelines.
Although most practitioners used CRRT, there was var-
iation in prescription of rate of UFNET. Unlike prescription 
for solute clearance, the optimal rate of UFNET for critically 
ill patients is unclear and one recent observational study 
found that UFNET rate greater than 1.75 mL/kg/hr was associ-
ated with increased risk of mortality compared with rate less 
than 1.01 mL/kg/hr (8), whereas other study found that rate 
greater than 25 mL/kg/d compared with rate less than 20 mL/
kg/d was associated with lower mortality (7). These differen-
tial findings suggest a need for clinical trials to determine op-
timal UFNET rate in various patient populations. Furthermore, 
there was a discrepancy between the prescribed-to-delivered 
dose of UFNET rate between physicians and nurses with nurses 
reporting lower rates. This finding may either represent true 
challenges to implementing the prescribed UFNET rates due 
to various reasons (e.g., hemodynamic instability). Only one 
third of practitioners assessed hourly net fluid balance during 
CRRT with significant variation among practitioners with re-
spect to timing of assessment of net fluid balance, which may 
be due to lack of evidence-based guidelines and constraints re-
lated to staffing.
Practitioners used a multipronged approach to tackle he-
modynamic instability with wide variation in practice, which 
has also been noted in prior studies (19). Such variation might 
be attributable to the absence of robust evidence to support 
treatment recommendations among critically ill patients. 
This is in stark contrast to the management of dialysis in the 
long-term setting, where there are well-established practice 
guidelines (20). Aside from patient intolerance, the most com-
mon barrier to achieving the target UFNET was interruptions, 
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unavailability of adequately trained staff, dialysis machines, 
and cost, a finding consistent with other studies (21, 22).
Practitioners favored early UFNET despite lack of evidence 
for such practice. Although FO was the main reason for start-
ing RRT among those allocated to the late arms of several 
randomized trials that examined the timing of initiation of 
RRT (23–25), none exclusively examined timing with respect 
to initiation of UFNET. Although many practitioners believed 
that a protocol would be beneficial, thematic analysis revealed 
that practitioners preferred use of functional hemodynamic 
monitoring and precision medicine approaches to individ-
ualize UFNET. Thus, further research is required to examine 
and validate functional hemodynamic monitoring and other 
approaches such as lactate to guide UFNET. Nevertheless, the 
majority of practitioners were willing to enroll patients in a 
clinical trial of protocol-based UFNET.
Our study has limitations. First, we were unable to determine 
the precise response rate as practitioners belonged to multiple 
societies and we were unable to track individual identities as 
well as due to challenges in conducting a web-based multina-
tional survey. Thus, there is a potential for selection bias due 
to nonrespondents. Nevertheless, our survey is the first to ex-
plore the international practice variation in UFNET. Second, the 
practitioners were mostly intensivists and ICU nurses; thus, we 
were unable to compare the responses with nephrologists and 
dialysis nurses, who may have different perspectives. Third, an 
inherent limitation of “self-reporting” is that the reliability of 
individual responses cannot be ensured and there is a possi-
bility of multiple similar responses from several participants 
from the same institution as well as potential for recall bias.
Fourth, the higher number of responses collected from 
some countries potentially reflect the care practices in those 
specific countries rather than the continent. Fifth, we did not 
study practice patterns in specific patient populations such 
as those on extracorporeal membrane oxygenation, medical/
surgical patients, or those with varying degrees of FO because 
our goal was to describe most common practice patterns in 
the ICU. Despite these limitations, this survey provides insight 
into the UFNET prescription and practice, which may help plan 
future research and quality implementation initiatives.
CONCLUSIONS
In this multinational survey, we found significant regional 
variation in prescription and practice of UFNET, which may be 
partly due to the absence of evidence-based recommendations 
and guidelines. Thus, there remains a compelling need for fur-
ther research to generate evidence to define best practices that 
improve patient outcomes and subsequently, interventions 
that reduce variation in practice.
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